AbbVie UK
Global biopharmaceutical company focused on discovery, development and delivery of innovative medicines across oncology, immunology, neuroscience, eye care and specialty areas. Operates R&D, clinical development, manufacturing and commercial functions, supports clinical trial transparency and investigator-initiated research, and maintains corporate programmes for ethics, compliance, transparency and community grants.
Industries
Nr. of Employees
medium (51-250)
AbbVie UK
AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire SL6 4UB, United Kingdom
Products
Immunology Medicines
Pharmaceutical treatments targeting immune system disorders to manage and treat related diseases.
Oncology Medicines
Pharmaceutical products aimed at treating various types of cancer by targeting cancer cells and related pathways.
Neuroscience Medicines
Medicines developed to treat neurological disorders affecting the brain and nervous system.
Eye Care Medicines
Pharmaceutical treatments for diseases and conditions affecting eye health and vision.
Virology Medicines
Medicines aimed at treating viral infections and diseases caused by viruses.
Women’s Health Medicines
Pharmaceutical products designed to address health issues specific to women, including reproductive and hormonal conditions.
Immunology Medicines
Pharmaceutical treatments targeting immune system disorders to manage and treat related diseases.
Oncology Medicines
Pharmaceutical products aimed at treating various types of cancer by targeting cancer cells and related pathways.
Neuroscience Medicines
Medicines developed to treat neurological disorders affecting the brain and nervous system.
Eye Care Medicines
Pharmaceutical treatments for diseases and conditions affecting eye health and vision.
Virology Medicines
Medicines aimed at treating viral infections and diseases caused by viruses.
Women’s Health Medicines
Pharmaceutical products designed to address health issues specific to women, including reproductive and hormonal conditions.
Services
Application-based support for investigator-led research projects aligned to company therapeutic interests.
Provides funding to eligible healthcare organisations and charities for projects in health, education, science and community support, reviewed by an internal committee.
Supports early access to investigational or authorised medicines through established schemes and local patient-support pathways.
Application-based support for investigator-led research projects aligned to company therapeutic interests.
Provides funding to eligible healthcare organisations and charities for projects in health, education, science and community support, reviewed by an internal committee.
Supports early access to investigational or authorised medicines through established schemes and local patient-support pathways.
Expertise Areas
- Clinical trial management and transparency
- Drug discovery and translational research
- Oncology research and targeted therapies
- Immunology research and precision medicine
Key Technologies
- Antibody-drug conjugates
- Targeted protein degradation
- Monoclonal antibodies
- Cellular therapies
News & Updates
Editorial stories intended for healthcare professionals, patients, policy makers and decision makers highlighting science, patients and collaborations.
Reported investment of approximately $63 billion in research since company launch in 2013.
Reported £60 million committed to research and development in the UK since 2018.
Reported 50,000+ employees operating in 70+ countries.
Reported $35 million donated to support COVID-19 relief efforts globally.
Reported support for 100 UK patients through an Early Access to Medicines scheme between 2017 and 2021.
Editorial stories intended for healthcare professionals, patients, policy makers and decision makers highlighting science, patients and collaborations.
Reported investment of approximately $63 billion in research since company launch in 2013.
Reported £60 million committed to research and development in the UK since 2018.
Reported 50,000+ employees operating in 70+ countries.
Reported $35 million donated to support COVID-19 relief efforts globally.
Reported support for 100 UK patients through an Early Access to Medicines scheme between 2017 and 2021.